ArticleJournal of thrombosis and thrombolysis2026
The von Willebrand factor/ADAMTS13 ratio as an indicator of venous thromboembolism risk: results from the RETROVE project.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The von Willebrand factor/ADAMTS13 ratio and shortened PFA-100 values have been associated with the risk of venous thromboembolism (VT). Our objective was to confirm the association of the VWF/ADAMTS13 ratio with VT risk and to assess the correlation between this ratio and PFA-100 values. We determined ADAMTS13 and VWF plasma levels, as well as PFA-100 values in 800 individuals (400 with VT and 400 healthy controls) from the RETROVE project. Using binary logistic regression and multivariate analyses, we evaluated the relationship between the VWF/ADAMTS13 ratio and VT risk. Quartile cut-offs of this ratio were calculated in controls, after which we estimated odds ratios (ORs) with 95% CIs. The risk of VT increased progressively with increasing quartiles of the VWF/ADAMTS13 ratio, with an OR of 4.12 (95% CI, 2.47-6.88) for the highest vs lowest quartiles in an age-adjusted analysis. When we analyzed the ROC curve for the VWF/ADAMTS13 ratio, we found similar results: we obtained three ranges of this ratio, with an increasingly progressive risk (ORs from 2.59 to 6.54). Values of the VWF/ADAMTS13 ratio correlated negatively with PFA-100 (R = - 0.5 p < 0.001). These findings indicate that the VWF/ADAMTS13 ratio is an indicator of VT risk and that a high ratio correlates negatively with PFA-100 values.
Indexed as
Identifiers
40813530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.